Patents by Inventor Andrew R. Chadeayne

Andrew R. Chadeayne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11358934
    Abstract: Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: June 14, 2022
    Assignee: CAAMTECH, INC.
    Inventor: Andrew R. Chadeayne
  • Patent number: 11332441
    Abstract: Crystalline N-methyl tryptamine derivatives, compositions containing those crystalline forms and their methods of use are disclosed. The crystalline N-methyl tryptamine derivatives according to the invention include crystalline N-methyl-N-propyltryptamine (MPT), crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate) and crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate).
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 17, 2022
    Assignee: CAAMTECH, INC.
    Inventor: Andrew R. Chadeayne
  • Publication number: 20220112162
    Abstract: The disclosure relates to a compound of formula (I): This disclosure also relates to a compound for formula (II): This disclosure also relates to a compound of formula (III): The disclosure also relates to crystalline compounds of formula (I), (II), or (III). The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I), (II), or (III) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I), (II), or (III) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I), (II), or (III).
    Type: Application
    Filed: October 6, 2021
    Publication date: April 14, 2022
    Applicant: CAAMTECH, INC.
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20210361679
    Abstract: Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Applicant: CAAMTECH, INC.
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20210353615
    Abstract: This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 18, 2021
    Applicant: CAAMTECH, INC.
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20210346346
    Abstract: Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 11, 2021
    Applicant: CAAMTECH, INC.
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20210300870
    Abstract: Crystalline N-methyl tryptamine derivatives, compositions containing those crystalline forms and their methods of use are disclosed. The crystalline N-methyl tryptamine derivatives according to the invention include crystalline N-methyl-N-propyltryptamine (MPT), crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate) and crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate).
    Type: Application
    Filed: March 23, 2020
    Publication date: September 30, 2021
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20210292278
    Abstract: Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.
    Type: Application
    Filed: March 23, 2020
    Publication date: September 23, 2021
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20210113644
    Abstract: Disclosed are compositions containing (a) a purified kratom compound chosen from the following: 7-Hydroxymitragynine, Mitragynine, Paynantheine, Speciociliatine, Speciogynine, Ajmalicine, Ciliaphylline, Corynantheidine, Corynoxine A, Corynoxine B, Isomitraphylline, Isorhynchophylline, Mitraphylline, Rhynchophylline, Speciophylline, Speciofoline, Epicatechin, 7-Hydroxyspecioliatine, 9-Hydroxycorynantheidine, Corynoxeine, Isopteropodine, Isorhynchophylline Oxindole, Tetrahydroalstonine, Mitragynine Oxindole B, and Mitragynine Oxindole A or the salts of these kratom compounds; and (b) a second active compound selected from a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, or a purified terpene. The disclosure also relates to formulations, including pharmaceutical formulations, of such a composition and an excipient.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 22, 2021
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20210085671
    Abstract: This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 25, 2021
    Applicant: CAAMTECH, LLC
    Inventor: Andrew R. CHADEAYNE
  • Patent number: 10933073
    Abstract: This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: March 2, 2021
    Assignee: CAAMTECH LLC
    Inventor: Andrew R. Chadeayne
  • Publication number: 20210023052
    Abstract: Disclosed are compositions containing (a) a purified toad secretion tryptamines chosen from the following 5-MeO-DMT, 5-MeO-NMT, 5-Methoxytryptamine, bufobutanoic Acid, bufobutarginine, bufoserotonin A, bufoserotonin B, bufoserotonin C, bufotenidine, bufotenin, bufotenin Oxide, bufotenine-O-Sulphate, bufoviridine, dET, dMT, n-Acetylserotonin, n?-Formylserotonin, n-Methylserotonin, o-Methylbufoviridine, serotonin, tryptamine, and bufopyramide or the salts of these toad secretion tryptamines and (b) a second active compound selected from a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, or a purified terpene. The disclosure also relates to formulations, including pharmaceutical formulations, of such a composition and an excipient. Also disclosed are methods of regulating the activity of a neurotransmitter receptor and methods of treating a psychological disorder, a compulsive disorder, or a depressive disorder.
    Type: Application
    Filed: July 23, 2020
    Publication date: January 28, 2021
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20190142851
    Abstract: This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 16, 2019
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20180221396
    Abstract: This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
    Type: Application
    Filed: February 9, 2018
    Publication date: August 9, 2018
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20160244703
    Abstract: Disclosed herein are new methods of preparing foods and beverages under the exclusion of oxygen have now been invented. In one embodiment, one or more of the food processing steps are performed under an inert atmosphere.
    Type: Application
    Filed: January 25, 2016
    Publication date: August 25, 2016
    Inventor: Andrew R. Chadeayne
  • Patent number: 9301909
    Abstract: Disclosed are methods of mitigating the effects of exposure to oxidizing agents, chlorinating and/or brominating agents on biological and/or synthetic fibers, by treating the body and/or clothing fibers with an effective amount of a composition comprising compounds of formula A. Also disclosed are compositions comprising compounds of formula A, for use in treating biological and/or synthetic fibers to mitigate the effects of exposure to chlorinating and/or brominating agents.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: April 5, 2016
    Inventor: Andrew R. Chadeayne
  • Publication number: 20130095055
    Abstract: Disclosed are methods of mitigating the effects of exposure to oxidizing agents, chlorinating and/or brominating agents on biological and/or synthetic fibers, by treating the body and/or clothing fibers with an effective amount of a composition comprising compounds of formula A. Also disclosed are compositions comprising compounds of formula A, for use in treating biological and/or synthetic fibers to mitigate the effects of exposure to chlorinating and/or brominating agents.
    Type: Application
    Filed: December 7, 2012
    Publication date: April 18, 2013
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20110111060
    Abstract: The present invention provides effective novel compositions and formulations for treating and/or preventing a hangover. The present invention also provides methods for treating and/or preventing a hangover comprising administering the compositions and/or formulations of the present invention.
    Type: Application
    Filed: June 24, 2009
    Publication date: May 12, 2011
    Inventor: Andrew R. Chadeayne